You have a great drug with poor management team. It doesn't matter how good the drug is, the the management team doesn't do their due diligence and work for increased shareholder's value.. i.e. Street realizes that all the value is going to Roche and the pathetic royalty rates mean very little to the bottom line for the company. What this management has done well is to dilute shareholder's value while increasing their own options reimbursements. Sad day!
I sort of agree with you, that it hurts to see Roche get almost all of the profits. And that this management puts it money interest (aka greed) ahead of the Company's shareholders, but this pathetic royalty rate was negotiated a long time ago by mostly different team, back when this was completely new and untested technology. This day, though, marks the unqualified validation of IMGN's technology. If we can bring our own drug to market, say for lung cancer, we will be up there with Amgen. BTW I bought more shares yesterday, and can wait another 10 years if that is what it takes, or never sell a share.